Navigation Links
CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
Date:1/5/2012

COPENHAGEN, Denmark and SEATTLE, Jan. 5, 2012 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical contract manufacturing organization, announced the issuance of European Patent No. US 2,171,034 B1 covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. The invention is designed to optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.

(Logo:  http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is continually innovating to advance biopharmaceutical manufacturing to the next level. Our expertise in developing efficient production processes puts our clients' projects in an optimal position to succeed," said Mads Laustsen, Chief Scientific Officer of CMC Biologics and Inventor.  "This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target."

 

Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment.  Optimal environmental conditions can be precisely controlled with this new technology resulting in increased productivity due to increased cell density in the reactor and in particular, a significant higher concentration of the product in the harvested medium. The expressed biologics are rapidly removed and made available for purification at high concentration — a significant advantage for the downstream processing.

 

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a global contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.

 

 


 


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Savient Submits Biologics License Application (BLA) for pegloticase
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
7. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
8. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
9. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016   MedyMatch Technology Ltd ., the ... intelligence, real-time decision support tools in the emergency room, announced ... 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... 15th National Life Sciences and Technology Week, and ... Intercontinental Hotel in Tel Aviv, Israel . ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2016. The cash dividend ... July 29, 2016 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:5/22/2016)... ... ... Doctors in Rome say micronutrients found in certain foods have the potential to ... posted an article on the new research. Click here to read it now. ... Medicine evaluated more than 150 studies on polyphenols in cancer for their report recently ...
(Date:5/19/2016)... ... 19, 2016 , ... Anton Paar USA, located in Ashland, Virginia is pleased ... The new structure adds a third office building to the current facilities. , ... acres of land, along with office space adjacent to the previous main building. Through ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/10/2016)... 10, 2016 --> ... report "Identity and Access Management Market by Component (Provisioning, ... Governance), by Organization Size, by Deployment, by Vertical, and ... MarketsandMarkets, The market is estimated to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
(Date:3/9/2016)... BEACH GARDENS, Fla. , March 9, 2016 ... identity management authentication and enrollment solutions, today announced ... DigitalPersona ® Altus multi-factor authentication ... IT and InfoSec managers to step-up security where ... Washington, DC . ...
Breaking Biology News(10 mins):